SynthesisEuropean journal of pediatrics2026
Efficacy of fluoroquinolone prophylaxis during induction phase in children with acute lymphoblastic leukemia: a systematic review and meta-analysis.
Synthesis in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of infection prevention with fluoroquinolone prophylaxis specifically, during induction chemotherapy in pediatric acute lymphoblastic leukemia (ALL), remains unclear. Therefore, we conducted a systematic review and meta-analysis to assess its efficacy. PubMed, Scopus, and Cochrane databases were systematically searched for randomized controlled trials and observational studies. The main outcome was febrile neutropenia (FN) 26 and secondary outcomes were bloodstream infection (BSI), Clostridioides difficile infection (CDI) and all-cause mortality (ACM). A random-effects meta-analysis was conducted. We included 7 studies with 991 patients; 439 (44.3%) used fluoroquinolone prophylaxis, of whom 255 used levofloxacin and 184 used ciprofloxacin. The B-cell immunophenotype was the most frequent. Fluoroquinolone prophylaxis reduced the risk of FN (46.1% vs 64.9%; OR 0.44; 95% CI 0.33-0.59; I
conclusionsFluoroquinolone prophylaxis during induction chemotherapy for pediatric ALL significantly reduces FN and BSI without increasing C. difficile risk. While overall mortality is unchanged, reducing infectious morbidity may enhance treatment tolerance. WHAT IS KNOWN: • Febrile neutropenia and bloodstream infections are major causes of treatment-related morbidity and mortality during induction chemotherapy in pediatric acute lymphoblastic leukemia and fluoroquinolone prophylaxis has shown inconsistent results across studies. • Prior evidence suggests potential reduction in infectious complications, but is limited by heterogeneous populations and lack of analyses specific for induction phase. WHAT IS NEW: • This systematic review and meta-analysis focused specifically on the induction phase of pediatric acute lymphoblastic leukemia and demonstrates that fluoroquinolone prophylaxis significantly reduces febrile neutropenia and bloodstream infections with consistent effect across study designs. • The study provides pooled estimate from an specific phase showing no clear increase in Clostridioides difficile infection, demonstrating the risk-benefit profile of fluoroquinolone prophylaxis.
Indexed as
Identifiers
42065773What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.